Intepirdine remains in clinical development for dementia with Lewy bodies (DLB), a disorder with a greater degree of cholinergic dysfunction that could be more responsive to subtle effects of this mechanism, and with a 70-mg top clinical dose, which could lead to a greater degree of 5-HT2A blockade and resulting benefits on other aspects of DLB beyond cognition. Here, HTR2A is linked to Lewy body dementia.